Fitness cost and benefit of antimicrobial resistance in : Multidisciplinary approaches are needed

English version České info

In a Perspective on the research article by Didelot and colleagues, Magnus Unemo and Christian Althaus discuss the value of modelling studies to inform antimicrobial resistance management and the limitations of the current evidence base informing such models.

Vyšlo v časopise: Fitness cost and benefit of antimicrobial resistance in : Multidisciplinary approaches are needed. PLoS Med 14(10): e32767. doi:10.1371/journal.pmed.1002423
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002423

Souhrn

Zdroje

1. Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, et al. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med. 2017;14: e1002344. doi: 10.1371/journal.pmed.1002344 28686231

2. Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis. 2017;17: e235–e279. doi: 10.1016/S1473-3099(17)30310-9 28701272

3. Alirol E, Wi TE, Bala M, Bazzo ML, Chen XS, Deal C, et al. Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. PLoS Med. 2017;14: e1002366. doi: 10.1371/journal.pmed.1002366 28746372

4. Public Health England. Surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP). Data up to October 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/567602/GRASP_Report_2016.pdf Cited 12 September 2017.

5. Cole MJ, Spiteri G, Jacobsson S, Woodford N, Tripodo F, Amato-Gauci AJ, et al. Overall low extended-spectrum cephalosporin resistance but high azithromycin resistance in Neisseria gonorrhoeae in 24 European countries, 2015. BMC Infectious Diseases. 2017;17: 617. doi: 10.1186/s12879-017-2707-z 28893203

6. Whittles LK, White PJ, Didelot X. Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: A modelling study. PLoS Med. 2017;14(10): e1002416. doi: 10.1371/journal.pmed.1002416

7. Bignell C, Fitzgerald M; Guideline Development Group; British Association for Sexual Health and HIV UK. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS. 2011;22: 541–547. doi: 10.1258/ijsa.2011.011267 21998172

8. Ison CA, Town K, Obi C, Chisholm S, Hughes G, Livermore DM, et al. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011. Lancet Infect Dis. 2013;13: 762–768. doi: 10.1016/S1473-3099(13)70143-9 23764300

9. Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, Van de Laar MJW. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill. 2013;18: 3.

10. Unemo M, Harris SR, Jacobsson S, Spiteri G, Tripodo F, Glasner C, et al. Whole genome sequencing for routine international molecular epidemiological surveillance of Neisseria gonorrhoeae: multidrug-resistant clones spreading in Europe in 2013. 20th International Pathogenic Neisseria Conference, Manchester, United Kingdom. September 4–9, 2016. Abstract O53.

11. Unemo M. Current and future antimicrobial treatment of gonorrhoea—the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15: 364. doi: 10.1186/s12879-015-1029-2 26293005

12. Shimuta K, Watanabe Y, Nakayama S, Morita-Ishihara T, Kuroki T, Unemo M, Ohnishi M. Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan. BMC Infect Dis. 2015;15: 378. doi: 10.1186/s12879-015-1110-x 26381611

13. Tanaka M, Furuya R, Irie S, Kanayama A, Kobayashi I. High prevalence of azithromycin-resistant Neisseria gonorrhoeae isolates with a multidrug resistance phenotype in Fukuoka, Japan. Sex Transm Dis. 2015;42: 337–341. doi: 10.1097/OLQ.0000000000000279 25970312

14. Yasuda M, Hatazaki K, Ito S, Kitanohara M, Yoh M, Kojima M, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae in Japan from 2000 to 2015. Sex Transm Dis. 2017;44: 149–153. doi: 10.1097/OLQ.0000000000000556 28178112

15. Fingerhuth SM, Bonhoeffer S, Low N, Althaus CL. Antibiotic-resistant Neisseria gonorrhoeae spread faster with more treatment, not more sexual partners. PLoS Pathog. 2016;12: e1005611. doi: 10.1371/journal.ppat.1005611 27196299

16. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: past, evolution, and future. Clin Microbiol Rev. 2014;27: 587–613. doi: 10.1128/CMR.00010-14 24982323

17. Tuite AR, Gift TL, Chesson HW, Hsu K, Salomon JA, Grad YH. Impact of rapid susceptibility testing and antibiotic selection strategy on the emergence and spread of antibiotic resistance in gonorrhea. J Infect Dis. jix450, https://doi.org/10.1093/infdis/jix450

18. Heffernan JM, Smith RJ, Wahl LM. Perspectives on the basic reproductive ratio. J R Soc Interface. 2005;2: 281–293. doi: 10.1098/rsif.2005.0042 16849186

19. Bignell C; IUSTI/WHO. 2009 European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2009;20: 453–457. doi: 10.1258/ijsa.2009.009160 19541885

20. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect. 2010;86: 422–426. doi: 10.1136/sti.2010.044586 20940153